1 / 5

Burt Adelman, M.D. Executive Vice President, Portfolio Strategy 5 June 2007

Burt Adelman, M.D. Executive Vice President, Portfolio Strategy 5 June 2007. Summit on Systems Biology 2007. R&D Investments by Research-Based Pharmaceutical Companies 1984-2005. Total NMEs approved each year. Expenditures ($ billions). 53. 55 50 45 40 35 30 25 20 15 10 5 0.

nura
Download Presentation

Burt Adelman, M.D. Executive Vice President, Portfolio Strategy 5 June 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Burt Adelman, M.D. Executive Vice President, Portfolio Strategy 5 June 2007 Summit on Systems Biology 2007

  2. R&D Investments by Research-Based Pharmaceutical Companies1984-2005 Total NMEs approved each year Expenditures ($ billions) 53 55 50 45 40 35 30 25 20 15 10 5 0 $39.4 22 18 $16.9 $3.6 Year Source: FDA; PhRMA Annual Survey, 2006

  3. Probability of Success from First Human Dose to Market by Therapeutic Area (based on NASs entering phase 1994-99) % Probability of Success % % % % % % % PARAXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006

  4. The Value Equation Safety + Efficacy Value

  5. What we Should be Doing Together • Understand human pathobiology • Focus industry research efforts on making drugs • Collaborate with the scientific community

More Related